Recently, news that the mRNA anti-cancer vaccine IntiSmeran has reached a major end in phase III experimental research has attracted great attention from the global pharmaceutical market. Some analysts pointed out that the technology is expected to rewrite the skin cancer treatment pattern, but its stock price may be overhyped. Miles Minter, an analyst at the US financial investment agency William Blair, estimates that if the vaccine is approved for melanoma treatment, the two cooperating companies can achieve a total sales revenue of 5.4 billion US dollars by 2040. However, some analysts believe that there is excessive hype about this news. The industry points out that melanoma has a high tumor mutation load, that is, there are a large number of mutations within the DNA, which is very suitable for this type of therapy. However, not all cancer tumors have this characteristic, which means that the vaccine's effects on melanoma may not be replicated in other cancers currently being tested, such as renal cell cancer and bladder cancer.

Recently, news that the mRNA anti-cancer vaccine IntiSmeran has reached a major end in phase III experimental research has attracted great attention from the global pharmaceutical market. Some analysts pointed out that the technology is expected to rewrite the skin cancer treatment pattern, but its stock price may be overhyped. Miles Minter, an analyst at the US financial investment agency William Blair, estimates that if the vaccine is approved for melanoma treatment, the two cooperating companies can achieve a total sales revenue of 5.4 billion US dollars by 2040. However, some analysts believe that there is excessive hype about this news. The industry points out that melanoma has a high tumor mutation load, that is, there are a large number of mutations within the DNA, which is very suitable for this type of therapy. However, not all cancer tumors have this characteristic, which means that the vaccine's effects on melanoma may not be replicated in other cancers currently being tested, such as renal cell cancer and bladder cancer.